Daily Chart:
http://stockcharts.com/h-sc/ui?s=FCSC&p=D&yr=0&mn=6&dy=0&id=p31219593597Weekly Chart:
http://stockcharts.com/h-sc/ui?s=FCSC&p=W&yr=0&mn=6&dy=0&id=p03418981184News:
http://finance.yahoo.com/q/h?s=FCSC+HeadlinesBusiness Summary: Fibrocell Science, Inc., a cellular aesthetic and therapeutic development stage biotechnology company, focuses on developing novel skin and tissue rejuvenation products. Its clinical development product candidates are designed to improve the appearance of skin injured by the effects of aging, sun exposure, acne, and burn scars with a patients own or autologous fibroblast cells produced by its proprietary Fibrocell process. The companys aesthetics development programs include product candidates to treat acne scarring and to provide full-face rejuvenation that includes the improvement of fine lines, wrinkles, skin texture, and appearance; and therapeutic development programs that are designed to treat restrictive burn scars and vocal scarring. Its lead product, LAVIV, is a personalized aesthetic cell therapy for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. Fibrocell Science, through its subsidiary, Agera Laboratories, Inc., also markets and sells a skin care product line in the United States and Europe. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was founded in 1995 and is headquartered in Exton, Pennsylvania.
Topic: FCSC - Fibrocell Science, Inc. - NYSE (Read 13321 times)
